News | Proton Therapy | November 20, 2015

Mevion to Install Three-Room Proton Therapy System in Los Angeles

Installation will be done in phases, with first room opening for treatments in late 2017

Mevion S250mx, Los Angeles Proton Center, three-room proton therapy system

Image courtesy of Mevion Medical Systems

November 20, 2015 – Mevion Medical Systems is announcing the Los Angeles Proton Center is building a three-room Mevion S250mx proton therapy system. The system will include Mevion’s Hyperscan pencil beam scanning technology and will be installed near Los Angeles, in the city of Montebello, on the campus of Beverly Hospital. The installation will take place in phases, with the first of the three rooms treating cancer patients in late 2017.

“The Mevion S250mx was the optimal solution for our facility because it allows for a flexible, phased installation,” said Charles Liu, president of the Los Angeles Proton Center. “Just as importantly, we continue to be impressed with the proven results of all of Mevion’s clinically operational systems, including Mevion’s industry-leading ramp-up time, high patient throughput, and low staffing and maintenance requirements. The decision to select Mevion and its product solutions will allow us to consistently provide high-quality proton therapy to a large number of patients.”

The Mevion S250mx is the fully scalable version of Mevion’s proton therapy technology and is available in two-, three- or four-room configurations. Each room is fully independent, with its own proton accelerator, providing inherent redundancy and 100 percent facility uptime 365 days per year. 

The Los Angeles Proton Center is an independent proton center that will collaborate with renowned cancer specialists to treat adult and pediatric cancer patients from the Greater Los Angeles area. The center will also serve international patients who are seeking cancer care on the West Coast of the United States.

Similar Mevion systems have ramped up to full capacity in as little as three months and achieved an annualized rate of 350 patients per room, per year. That is more than 25 percent better than the average U.S. proton therapy center. 

The Los Angeles system is the third system purchase announced by Mevion in the past six weeks. In October, Mevion announced the installation of a Mevion S250 to Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland, and a Mevion S250i with Hyperscan to the Ackerman Cancer Center in Jacksonville, Florida.

Hyperscan has not been cleared by the U.S. Food and Drug Administration for clinical use.

For more information:

Related Content

IBA Releases Razor Nano Ionization Chamber
News | Proton Therapy | September 22, 2017
September 22, 2017 — IBA (Ion Beam Applications S.A.) announced the release of the Razor Nano Chamber, the smallest a
Penn Medicine Treats World's First Patient on Varian's Halcyon System
News | Radiation Therapy | September 22, 2017
September 22, 2017 — Varian Medical Systems announced a patient at Penn Medicine, with head & neck cancer, became
BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Overlay Init